SCHEMBL8614836

SCHEMBL8614836

Cc1cccc(-c2cc(C(=O)O)c3ccccc3n2)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.75
LMNA P02545 4/20 0.75
SMN1; SMN2 Q16637 3/20 0.75
PDE10A Q9Y233 1/20 0.75
AKR1C3 P42330 1/20 0.72
AKR1C2 P52895 1/20 0.72
AKR1C1 Q04828 1/20 0.72
DHODH Q02127 4/20 0.71
ALDH1A1 P00352 5/20 0.70
HSD17B10 Q99714 1/20 0.70
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
MAPT P10636 3/20 0.64
POLB P06746 1/20 0.63
NPC1 O15118 2/20 0.61
RAB9A P51151 2/20 0.61
HTT P42858 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
HPGD P15428 1/20 0.61
NFKB1 P19838 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30690078 0.87 DHODH (0.68) KDM4ELMNASMN1; SMN2DHODHALDH1A1
SCHEMBL7094226 0.87 DHODH (0.68) KDM4ELMNASMN1; SMN2DHODHALDH1A1
Cinchophen SCHEMBL29376617 0.86 KDM4E (1.00) KDM4ELMNASMN1; SMN2PDE10AAKR1C3
Cinchophen SCHEMBL25519 0.86 KDM4E (1.00) KDM4ELMNASMN1; SMN2PDE10AAKR1C3
Cinchophen SCHEMBL7588217 0.86 KDM4E (1.00) KDM4ELMNASMN1; SMN2PDE10AAKR1C3
SCHEMBL4017739 0.85 DHODH (0.80) KDM4ELMNASMN1; SMN2PDE10ADHODH
SCHEMBL29788466 0.85 DHODH (0.80) KDM4ELMNASMN1; SMN2PDE10ADHODH
Cinchophen SCHEMBL4464779 0.85 KDM4E (0.97) KDM4ELMNASMN1; SMN2PDE10AAKR1C3
Cinchophen SCHEMBL10757475 0.85 KDM4E (0.97) KDM4ELMNASMN1; SMN2PDE10AAKR1C3
Cinchophen SCHEMBL4805149 0.85 KDM4E (0.97) KDM4ELMNASMN1; SMN2PDE10AAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4617270-A1 ISOINDOLINONE DERIVATIVE HAVING QUINOLINE AMIDE STRUCTURE, AND USE THEREOF Oncord Bio Inc (KR) 2025-09-17 EP disclosed
CN-120152966-A Isoindolinone derivative with quinolinamide structure and application thereof 昂科德生物株式会社 2025-06-13 CN disclosed
US-20240024490-A1 BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES THE BROAD INSTITUTE, INC. 2024-01-25 US disclosed
US-20230192904-A1 BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF THE BROAD INSTITUTE, INC. 2023-06-22 US disclosed
EP-0726254-B1 Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds MITSUI TOATSU CHEMICALS (JP) 1998-05-06 EP disclosed
US-5627193-A MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION MITSUI TOATSU CHEMICALS, INC. (JP) 1997-05-06 US disclosed
EP-0726254-A1 Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds MITSUI TOATSU CHEMICALS, Inc. (JP) 1996-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024490-A1 BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES COASY, JMJD7, PTMS KDM4E 2788/4885LMNA 4027/4885SMN1; SMN2 3607/4885
US-20230192904-A1 BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF ERBB2, ACP1, TK1 KDM4E 2301/4885LMNA 1883/4885SMN1; SMN2 3469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.